VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ABT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ABTAbbott Laboratories
$104.71$182.4B
Overview & Tools
OverviewChart Terminal ↗AnalysisVisualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksABTBalance Sheet

Abbott Laboratories (ABT) Balance Sheet

30Y historyFree accessUpdated daily

Total debt rose from $13.2B to $34.0B before easing to $31.2B, pushing debt-to-equity from 0.25 to 0.65 and then to 0.60, while cash fell from $8.5B at year-end 2025 to $4.1B, indicating a sharp event-driven leverage shift that has thinned the liquidity buffer.

Income StatementBalance SheetCash FlowRatios

ABT Balance Sheet

Annual statement

ABT Balance Sheet

Abbott Laboratories (ABT) balance sheet — 30-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Total Current Assets23.5B26B23.66B22.67B25.22B24.24B20.44B15.67B14.63B20.15B26.78B14.15B15.26B19.25B31.32B23.77B22.32B23.31B17.04B14.04B11.28B11.39B10.73B10.29B9.12B8.42B7.38B6.42B5.55B5.04B4.48B
Cash & Short-Term Investments4.3B8.94B7.97B7.28B10.17B10.25B7.15B4.14B4.09B9.61B18.77B6.13B4.46B8.1B15.17B8.1B7.32B9.93B5.08B2.82B1.37B2.96B2.06B1.29B966.13M713.54M1.16B723.3M383.32M259.01M123.08M
Cash Only4.05B8.52B7.62B6.9B9.88B9.8B6.84B3.86B3.84B9.41B18.62B5B4.06B3.48B10.8B6.81B7.32B8.81B4.11B2.46B521.19M2.89B2.06B995.12M704.45M657.38M914.22M608.1M308.23M230.02M110.21M
Short-Term Investments246M417M351M383M288M450M310M280M242M203M155M1.12B397M4.62B4.37B1.28B01.12B967.6M364.44M852.24M62.41M0291.3M261.68M56.16M242.5M115.2M75.09M28.99M12.88M
Accounts Receivable9.03B7.93B6.92B6.57B6.22B6.49B6.41B5.42B5.18B5.25B3.25B3.42B3.59B3.99B7.61B7.68B7.18B6.54B5.47B4.95B4.23B3.58B3.7B3.31B2.93B2.81B2.18B2.06B1.96B1.78B1.71B
Days Sales Outstanding63.8965.2960.2559.7451.9954.9767.6562.0761.8669.9556.8561.1464.6566.5969.6972.1974.5677.6167.5669.6868.7158.4468.5561.4560.4263.0457.8756.9457.2154.7456.63
Inventory7.34B6.49B6.19B6.57B6.17B5.16B5.01B4.32B3.8B3.6B2.43B2.6B2.64B2.69B3.79B3.28B3.19B3.26B2.78B2.95B2.81B2.54B2.62B2.74B2.44B2.21B1.74B1.5B1.41B1.28B1.24B
Days Inventory Outstanding123.88120.08109.61119.47105.6394.77106.17103.5793.991.7692.46100.4498.87100.3130.1277.7979.8690.6581.1795.1106.3288.64107.66105.51104.76104.2101.8891.3295.4492.5995.51
Other Current Assets2.83B2.64B2.57B2.26B2.66B2.35B1.87B1.79B1.57B1.69B2.32B2.01B2.87B4.47B4.74B4.7B4.62B3.58B3.72B3.32B2.87B2.31B2.36B1.17B1.02B1.11B001.05M28.93M12.89M
Total Non-Current Assets84.75B60.72B57.76B50.54B49.21B50.96B52.11B52.22B52.54B56.1B28.23B29.85B30.23B23.71B35.91B36.51B38.26B29.27B25.38B25.67B24.9B17.76B18.03B16.42B15.14B14.88B7.91B8.05B7.66B7.02B6.64B
Property, Plant & Equipment12.88B12.94B11.73B11.28B10.28B10.11B10.13B8.97B7.56B7.61B5.71B5.73B5.93B5.91B8.06B7.87B7.97B7.62B7.22B7.52B6.95B6B6.01B6.28B5.83B5.55B4.82B4.77B4.74B4.57B4.46B
Fixed Asset Turnover3.78x3.43x3.58x3.56x4.25x4.26x3.42x3.56x4.04x3.60x3.66x3.56x3.41x3.70x4.95x4.93x4.41x4.04x4.09x3.45x3.24x3.72x3.28x3.13x3.03x2.93x2.85x2.76x2.63x2.60x2.47x
Goodwill32.64B24.04B23.11B23.68B22.8B23.23B23.74B23.2B23.25B24.02B7.68B9.64B10.07B9.77B15.77B15.71B15.93B13.2B9.99B10.13B9.45B5.22B5.69B00000000
Intangible Assets19.59B5.53B6.65B8.81B10.45B12.74B14.78B17.02B18.94B21.47B4.54B5.56B6.2B5.74B8.59B9.99B12.15B6.29B5.15B5.72B6.4B4.74B5.17B8.54B7.65B7.29B1.56B1.57B1.35B1.11B979.79M
Long-Term Investments4.22B918M886M799M766M903M1.03B931M897M883M2.95B4.04B229M119M274M378.23M302.05M1.13B1.07B1.13B1.23B134.01M291.49M77M271.65M-1.38B00000
Other Non-Current Assets18.54B17.3B15.38B5.97B4.92B3.97B2.42B2.1B1.89B2.12B3.35B492M3B2.17B3.21B2.56B1.9B1.02B1.95B1.18B867.08M1.66B876.93M329.36M-20.87M2.03B1.53B1.71B1.57B1.34B1.2B
Total Assets108.25B86.71B81.41B73.21B74.44B75.2B72.55B67.89B67.17B76.25B55.01B44B43.79B42.95B67.23B60.28B60.57B52.58B42.42B39.71B36.18B29.14B28.77B26.72B24.26B23.3B15.28B14.47B13.22B12.06B11.13B
Asset Turnover0.47x0.51x0.52x0.55x0.59x0.57x0.48x0.47x0.46x0.36x0.38x0.46x0.46x0.51x0.59x0.64x0.58x0.59x0.70x0.65x0.62x0.77x0.68x0.74x0.73x0.70x0.90x0.91x0.94x0.99x0.99x
Asset Growth %100.7%6.51%11.2%-1.64%-1.01%3.65%6.87%1.06%-11.9%38.61%25.02%0.48%1.95%-36.12%11.54%-0.49%15.2%23.96%6.81%9.77%24.15%1.3%7.68%10.13%4.13%52.43%5.61%9.49%9.58%8.41%18.2%
Total Current Liabilities16.15B16.5B14.16B13.84B15.49B13.11B11.91B10.86B9.01B8.91B6.66B9.19B10.53B9.51B13.28B15.48B17.26B13.05B11.59B9.1B11.95B7.42B6.83B7.64B7B7.93B4.3B4.52B4.96B5.03B4.34B
Accounts Payable4.66B4.24B4.2B4.29B4.61B4.41B3.95B3.25B2.98B2.4B1.18B1.08B1.06B1.03B1.8B1.72B1.54B1.28B1.35B1.22B1.18B1.03B1.05B1.08B1.66B1.53B1.36B1.23B1.06B1B923M
Days Payables Outstanding80.978.4774.2478.178.8481.0183.5978.0373.5961.2144.7541.7739.838.2161.6540.7638.4635.5639.5239.2944.5436.0143.3241.5571.371.8579.3374.9271.5572.4271.2
Short-Term Debt1.71B3.31B1.75B1.32B2.48B999M461M1.68B207M714M1.32B3.13B4.44B3.17B2.39B3.37B6.39B5.19B2.73B2.73B5.4B2.06B1.99B2.54B2.15B2.95B479.45M896.27M1.76B1.78B1.38B
Deferred Revenue (Current)000000000000000000000002.18B2.2B2.29B1.55B1.43B1.38B1.41B1.21B
Other Current Liabilities7.89B5.54B5.91B6.13B6.5B5.77B5.72B4.46B4.34B4.3B3.22B3.8B3.92B4.23B7.01B8.61B6.7B5.02B5.69B4.22B4.3B3.21B2.98B1.84B989.42M1.16B912.86M960.16M766.94M845.88M830.44M
Current Ratio1.45x1.58x1.67x1.64x1.63x1.85x1.72x1.44x1.62x2.26x4.02x1.54x1.45x2.02x2.36x1.54x1.29x1.79x1.47x1.54x0.94x1.54x1.57x1.35x1.30x1.06x1.72x1.42x1.12x1.00x1.03x
Quick Ratio1.00x1.18x1.23x1.16x1.23x1.46x1.30x1.04x1.20x1.86x3.65x1.26x1.20x1.74x2.07x1.32x1.11x1.54x1.23x1.22x0.71x1.19x1.19x0.99x0.95x0.78x1.31x1.09x0.83x0.75x0.75x
Cash Conversion Cycle106.88106.8995.63101.1178.7968.7390.2387.682.17100.5104.56119.8123.72128.68138.16109.21115.96132.71109.21125.48130.5111.08132.89125.4193.8795.480.4273.3581.1174.9180.94
Total Non-Current Liabilities40.47B17.45B19.36B20.55B22.04B26.07B27.64B25.72B27.44B36.24B27.63B13.49B11.69B8.18B27.14B20.27B20.55B16.34B13.35B12.83B10.17B7.31B7.62B6B6.59B6.31B2.41B2.53B2.54B2.03B1.96B
Long-Term Debt29.45B10.83B12.63B13.6B14.52B17.3B18.53B16.66B19.36B27.21B20.68B5.87B3.39B3.39B18.09B12.04B12.52B11.27B8.71B9.49B7.01B4.57B4.79B3.45B4.27B4.34B1.08B1.34B1.34B937.98M932.9M
Capital Lease Obligations931M931M896M949M943M956M902M755M00000000000000000000000
Deferred Tax Liabilities1.96B1.96B1.37B1.22B1.84B2.07B2.15B2.13B2.06B2.01B2.7B3.56B3.46B466M710M703M1.11B165M000583.08M220.08M000023.78M108.96M136.51M153.28M
Other Non-Current Liabilities11.02B3.73B4.46B4.78B4.74B5.74B6.06B6.18B6.02B7.02B4.25B4.06B4.84B4.33B8.35B7.53B6.91B4.91B4.63B3.34B3.16B2.16B2.61B2.55B2.32B1.97B1.34B1.17B1.09B953.43M875.52M
Total Liabilities56.62B33.94B33.51B34.39B37.53B39.17B39.55B36.59B36.45B45.15B31.95B19.92B19.64B17.69B40.42B35.75B36.99B29.52B24.94B21.94B22.12B14.73B14.44B13.64B13.59B14.24B6.71B7.04B7.5B7.06B6.31B
Total Debt31.16B15.07B15.28B15.87B17.95B19.25B19.89B19.1B19.57B27.92B22.01B9B7.83B6.56B20.48B15.41B18.92B16.46B11.45B12.21B12.41B6.63B6.78B5.99B6.42B7.29B1.56B2.23B3.1B2.72B2.32B
Net Debt27.11B6.54B7.66B8.98B8.06B9.45B13.05B15.24B15.72B18.52B3.39B4B3.77B3.09B9.67B8.6B11.59B7.65B7.33B9.76B11.89B3.74B4.72B4.99B5.72B6.63B641.6M1.62B2.79B2.49B2.21B
Debt / Equity0.60x0.29x0.32x0.41x0.49x0.53x0.60x0.61x0.64x0.90x1.06x0.42x0.36x0.26x0.76x0.63x0.83x0.71x0.65x0.69x0.88x0.46x0.47x0.46x0.60x0.80x0.18x0.30x0.54x0.54x0.48x
Debt / EBITDA2.83x1.35x1.52x1.64x1.54x1.51x2.31x2.51x2.75x5.59x4.78x2.04x1.78x1.79x4.27x1.56x1.96x1.90x1.44x1.80x2.11x1.10x1.24x1.46x1.53x2.38x0.37x0.56x0.79x0.76x0.70x
Net Debt / EBITDA2.46x0.59x0.76x0.93x0.69x0.74x1.51x2.00x2.21x3.71x0.74x0.90x0.86x0.84x2.02x0.87x1.20x0.88x0.92x1.43x2.02x0.62x0.86x1.22x1.36x2.17x0.15x0.41x0.72x0.70x0.67x
Interest Coverage7.72x25.83x12.63x10.55x27.37x21.03x8.02x5.98x4.94x3.54x5.65x18.88x16.35x44.43x1.75x6.11x8.13x35.15x12.08x8.54x6.47x20.14x21.61x21.04x15.88x0.01x146.44x----
Total Equity51.62B52.77B47.9B38.83B36.91B36.02B33B31.3B30.72B31.1B20.72B21.33B21.64B25.27B26.81B24.53B22.77B23.19B17.48B17.78B14.05B14.42B14.33B13.07B10.66B9.06B8.57B7.43B5.71B5B4.82B
Equity Growth %20.12%10.17%23.37%5.21%2.45%9.15%5.44%1.88%-1.21%50.11%-2.86%-1.45%-14.36%-5.77%9.32%7.74%-1.82%32.65%-1.68%26.5%-2.5%0.62%9.59%22.58%17.72%5.7%15.39%30%14.3%3.7%9.63%
Book Value per Share29.7030.2127.4022.2020.9220.1418.4817.5717.3617.7813.9714.1614.1716.0516.8415.6214.6314.9111.2011.409.159.229.128.326.785.785.474.773.663.173.05
Total Shareholders' Equity51.03B52.13B47.66B38.6B36.69B35.8B32.78B31.09B30.52B30.9B20.54B21.21B21.53B25.17B26.72B24.44B22.68B23.14B17.48B17.78B14.05B14.42B14.33B13.07B10.66B9.06B8.57B7.43B5.71B5B4.82B
Common Stock25.64B25.53B25.15B24.87B24.71B24.47B24.14B23.85B23.51B23.21B13.03B12.73B12.38B12.05B11.76B9.82B8.74B8.26B7.44B6.1B4.29B3.52B3.24B3.03B2.89B2.64B2.22B1.94B1.23B907.11M694.38M
Retained Earnings49.64B49.78B47.26B37.55B35.26B31.53B27.63B25.85B24.56B23.98B25.57B25.76B22.87B21.98B24.15B20.91B18.93B17.05B13.83B10.81B9.57B10.4B10.03B9.69B8.6B7.28B7.23B6.17B4.55B4.43B4.26B
Treasury Stock-17.91B-17.18B-16.84B-15.98B-15.23B-11.82B-10.04B-10.15B-9.96B-10.22B-10.79B-10.62B-8.68B-6.84B-5.59B-3.69B-3.92B-3.31B-2.63B-1.21B-195.24M-212.25M-220.85M-229.7M-231.84M-252.44M-255.59M-257.76M-46.7M-48.24M-50.6M
Accumulated OCI-6.34B-6B-7.91B-7.84B-8.05B-8.37B-8.95B-8.46B-7.59B-6.06B-7.26B-6.66B-5.05B-2.01B-3.59B-2.6B-1.37B854.07M-1.16B2.08B389.77M699.19M1.27B576.42M-596.25M-612.97M-621.33M-428.33M-25.33M-288.19M-86.4M
Minority Interest596M641M237M224M219M222M219M213M198M201M179M115M113M96M92.27M86.31M88.33M43.1M39.14M000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetMixed
Cash FlowMixed
Top Statement Risk

Legal exposure and leverage volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Leverage Swings Mask Underlying Stability

Based on reported quarterly balance sheets, ABT's total debt rose from $13.2B to $34.0B and then fell to $31.2B, while its debt-to-equity ratio moved from 0.25 to 0.65 before retreating to 0.60, pointing to a sharp, event-driven shift in capital structure rather than a gradual trend.

The jump in total assets and goodwill from roughly $24B to $35B alongside rising debt suggests an acquisition-led expansion funded partly by borrowing. Retained earnings have stayed close to $50B, which indicates the equity base has been stable rather than eroded, so the leverage spike appears more like a financing choice than a sign of operating stress. Investors should monitor whether debt continues to decline as the reported figures imply.

Debt Reduction Eases Refinancing Pressure

According to the reported filings, ABT reduced total debt from $34.0B in Q1 2026 to $31.2B in Q3 2026, bringing debt-to-equity down to 0.60, a reduction that lowers near-term refinancing exposure but still leaves leverage well above the 2025 levels.

Debt-to-equity of 0.60 remains moderate relative to MDT at 0.56 and BSX at 0.51, while BAX at 1.64 shows the sector includes far more levered balance sheets. The pace of repayment implies management is prioritizing deleveraging, which may suggest the 2026 borrowing was tied to a discrete transaction. Whether the remaining debt load is sustainable depends on free cash flow holding up through quarters where working capital has been volatile.

Cash Buffer Thins as Debt Is Repaid

Based on ABT's reported figures, cash fell from $8.5B at year-end 2025 to $4.1B in Q3 2026 while the current ratio eased from 1.58 to 1.45, indicating that liquidity has been drawn down as debt was retired.

A current ratio near 1.45 remains adequate for a company of this scale, but the sharp cash decline reduces the buffer available against operating shocks such as product recalls or litigation settlements. The reported figures suggest the company has been using cash to service obligations rather than building reserves. Investors should watch whether cash rebuilds in coming quarters or whether reliance on operating cash flow increases.

Goodwill Expansion Raises Impairment Exposure

As reported in the balance sheets, ABT's goodwill climbed from $23.4B to $35.2B during 2026 before easing to $32.6B, representing a large share of total assets that now sits near $108B and warrants close attention to future impairment risk.

Goodwill now accounts for roughly 30% of total assets, which increases sensitivity to any deterioration in the earnings of acquired businesses such as the diagnostics and nutrition units. Net PPE of about $12.9B is comparatively modest, indicating an asset base weighted toward intangibles rather than physical capacity. The reported figures suggest that the quality of the asset base depends heavily on whether acquired franchises continue to generate returns that justify their carrying values.

Deferred Revenue Absence Limits Visibility

Based on the reported balance sheets, ABT carries no disclosed deferred revenue in any of the ten quarters, which removes a conventional forward indicator and means the headline balance sheet offers little direct evidence about future contracted demand.

The absence of deferred revenue is not itself evidence of weakness, but it limits the ability to read forward demand from the balance sheet alone, particularly for the consumable diagnostics and sensor businesses. Combined with a 32% concentration of tracked risk factors in legal and regulatory matters, this gap suggests analysts should rely more on segment disclosures than balance sheet signals. The data available does not allow firm conclusions about backlog or unearned obligations.

ABT — Frequently Asked Questions

Quick answers to the most common questions about buying ABT stock.

What are the total assets of Abbott Laboratories (ABT)?

As of 2025, Abbott Laboratories (ABT) had total assets of $86.71B including $26.00B in current assets.

How much debt does Abbott Laboratories (ABT) have?

Abbott Laboratories (ABT) carries total debt of $15.07B, offset by $8.94B in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Abbott Laboratories?

Abbott Laboratories (ABT) has total shareholders' equity (book value) of $52.13B ($30.21 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Abbott Laboratories's current ratio and liquidity?

Abbott Laboratories (ABT) reported a current ratio of 1.58x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.